BeOne Medicines Ltd
220 hedge funds and large institutions have $10.3B invested in BeOne Medicines Ltd in 2023 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 71 increasing their positions, 63 reducing their positions, and 29 closing their positions.
111% more call options, than puts
Call options by funds: $37.3M | Put options by funds: $17.7M
31% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 29
13% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 63
4% more funds holding
Funds holding: 212 → 220 (+8)
0.14% less ownership
Funds ownership: 3.66% → 3.52% (-0.14%)
5% less capital invested
Capital invested by funds: $10.9B → $10.3B (-$581M)
8% less funds holding in top 10
Funds holding in top 10: 12 → 11 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$75.5M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$44.1M |
| 3 |
AI
Axiom Investors
Greenwich,
Connecticut
|
+$39.7M |
| 4 |
State Street
Boston,
Massachusetts
|
+$24M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$20.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$323M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$50.8M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$48.3M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$39.2M |
| 5 |
Temasek Holdings
Singapore
|
-$34.4M |
ONC Hedge Fund Activity: Q1 2023 in Review
220 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines Ltd (ONC) for Q1 2023, worth a combined $10.3B — down 5.3% from $10.9B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new ONC positions and 29 closed out — a net gain of 9 holders — while 71 added to existing stakes and 63 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $75.5M. The largest seller was Invesco, cutting an estimated $323M.
- 220 institutional investors held BeOne Medicines Ltd (ONC) as of Q1 2023, up from 212 in Q4 2022.
- Funds reported $10.3B of BeOne Medicines Ltd stock for Q1 2023, down 5.3% quarter-over-quarter.
- 38 funds opened new BeOne Medicines Ltd positions in Q1 2023 and 29 closed out, a net change of +9 holders.
- The largest BeOne Medicines Ltd buyer in Q1 2023 was T. Rowe Price Associates, an estimated $75.5M added.
- The largest BeOne Medicines Ltd seller in Q1 2023 was Invesco, an estimated $323M sold.
Based on aggregated 13F filings for Q1 2023.